Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, Forstbauer H, Tio J, Grischke EM, Biehl C, Liedtke C, De Haas SL, Deurloo R, Wuerstlein R, Kreipe HH, Gluz O. Harbeck N, et al. Among authors: grischke em. Cancers (Basel). 2021 Sep 29;13(19):4884. doi: 10.3390/cancers13194884. Cancers (Basel). 2021. PMID: 34638369 Free PMC article.
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA. Harbeck N, et al. Among authors: grischke em. J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6. J Clin Oncol. 2017. PMID: 28682681 Clinical Trial.
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: grischke em. J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258. J Natl Cancer Inst. 2018. PMID: 29228315 Clinical Trial.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R, Kates R, Gluz O, Grischke EM, Schem C, Thill M, Hasmueller S, Köhler A, Otremba B, Griesinger F, Schindlbeck C, Trojan A, Otto F, Knauer M, Pusch R, Harbeck N; WSG-PRIMe investigators in Germany, Austria, Switzerland. Wuerstlein R, et al. Among authors: grischke em. Breast Cancer Res Treat. 2019 Jun;175(2):389-399. doi: 10.1007/s10549-018-05075-x. Epub 2019 Feb 22. Breast Cancer Res Treat. 2019. PMID: 30796651 Free PMC article. Clinical Trial.
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA).
Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Lübbe K, Marmé F, Maass N, von Minckwitz G, Grischke EM, Müller V, Schmidt M, Gerber B, Kümmel S, Schumacher C, Krabisch P, Seiler S, Thill M, Nekljudova V, Loibl S. Bischoff J, et al. Among authors: grischke em. Anticancer Drugs. 2019 Apr;30(4):394-401. doi: 10.1097/CAD.0000000000000722. Anticancer Drugs. 2019. PMID: 30875348 Clinical Trial.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Gluz O, Kolberg-Liedtke C, Prat A, Christgen M, Gebauer D, Kates R, Paré L, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kuemmel S, Wuerstlein R, Pelz E, Nitz U, Kreipe HH, Harbeck N. Gluz O, et al. Among authors: grischke em. Int J Cancer. 2020 Jan 1;146(1):262-271. doi: 10.1002/ijc.32488. Epub 2019 Jun 19. Int J Cancer. 2020. PMID: 31162838 Free article. Clinical Trial.
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Nitz U, Gluz O, Kreipe HH, Christgen M, Kuemmel S, Baehner FL, Shak S, Aktas B, Braun M, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Nuding B, Darsow M, Schumacher C, Krauss K, Malter W, Thill M, Warm M, Wuerstlein R, Kates RE, Harbeck N. Nitz U, et al. Among authors: grischke em. Ther Adv Med Oncol. 2020 Nov 23;12:1758835920973130. doi: 10.1177/1758835920973130. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33281950 Free PMC article.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Graeser M, Schrading S, Gluz O, Strobel K, Würstlein R, Kümmel S, Schumacher C, Grischke EM, Forstbauer H, Braun M, Christgen M, Adams J, Nitzsche H, Just M, Fischer HH, Aktas B, Potenberg J, von Schumann R, Kolberg-Liedtke C, Harbeck N, Kuhl CK, Nitz U. Graeser M, et al. Among authors: grischke em. Int J Cancer. 2021 May 15;148(10):2614-2627. doi: 10.1002/ijc.33495. Epub 2021 Feb 11. Int J Cancer. 2021. PMID: 33533487 Free PMC article.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Wuerstlein R, Harbeck N, Grischke EM, Forstmeyer D, von Schumann R, Krabisch P, Lüdtke-Heckenkamp K, Stefek A, Stoetzer O, Grafe A, Kaltenecker G, Forstbauer H, Augustin D, Schrader I, Tio J, Nitz U, Gluz O, Kates RE, Graeser MK. Wuerstlein R, et al. Among authors: grischke em. Breast Care (Basel). 2021 Feb;16(1):50-58. doi: 10.1159/000506622. Epub 2020 Apr 6. Breast Care (Basel). 2021. PMID: 33716632 Free PMC article.
169 results